NanoViricides, Inc. — Form 10-Q Summary
Period clarification: The request labels this “2021 Q3,” but the filing is for the quarter and nine months ended March 31, 2022 (the company’s fiscal third quarter), filed May 16, 2022. The financial statements are unaudited.
Business context and reporting period
NanoViricides is a pre-revenue antiviral drug developer with a nanomedicine platform and in-house manufacturing facilities. Its lead priority is developing COVID-19 candidates NV-CoV-2 and NV-CoV-2-R for clinical testing; the shingles candidate NV-HHV-101 and other antiviral programs are also in development. The company has no commercial products or customers.
Financial results and liquidity
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $1.26 million (2022); $1.46 million (2021) | $4.61 million (2022); $4.53 million (2021) |
| General and administrative expense | $0.53 million (2022); $0.64 million (2021) | $1.71 million (2022); $2.14 million (2021) |
| Net loss | $1.79 million (2022); $2.11 million (2021) | $6.33 million (2022); $6.75 million (2021) |
| Basic and diluted loss per share | $0.16 (2022); $0.19 (2021) | $0.55 (2022); $0.63 (2021) |
| Net cash used in operating activities | Not presented for the quarter | $4.49 million (2022); $5.99 million (2021) |
At March 31, 2022, cash and cash equivalents were $15.57 million, down from $20.52 million at June 30, 2021. Total assets were $25.14 million and stockholders’ equity was $24.76 million. Current liabilities were $386,731, including a $164,905 short-term insurance-financing loan; the company reported no long-term debt. Net property and equipment was $8.80 million. Gross margin is not applicable because the company reported no revenue.
Cash declined by $4.94 million over the nine-month period. Investing outflows were $248,986, principally property and equipment purchases; financing outflows were $202,007. The company reported an accumulated deficit of $120.71 million.
Changes versus the prior comparable period
- Nine-month net loss narrowed by about $422,000, while operating cash use fell by about $1.49 million.
- Nine-month R&D expense increased about $83,000, principally reflecting a $935,088 non-cash Series A preferred-stock license milestone to TheraCour, partly offset by lower outside-laboratory costs.
- Nine-month G&A expense decreased about $432,000, mainly from lower professional fees and general operating costs.
- Cash fell from the prior fiscal year-end despite the lower operating cash burn. Common shares outstanding increased from 11.52 million at June 30, 2021 to 11.55 million at March 31, 2022; preferred shares also increased.
Outlook, risks, and unusual items
- Management estimated available resources would fund planned operations through May 15, 2023, and stated funds were sufficient for initial human clinical trials of at least one candidate. The filing also says additional capital will be needed for longer-term operations and further trials; clinical development is expected to increase spending.
- The COVID-19 candidates had completed reported preclinical safety work, and the company was preparing regulatory submissions and trial arrangements. No human clinical trial had begun; the filing gives no reliable start date and cites regulatory, site-capacity, and collaboration dependencies.
- Management’s efficacy and safety statements for COVID-19 candidates rely on preclinical studies and company-reported results, not human clinical evidence. Trial outcomes, regulatory acceptance, manufacturing readiness, and future financing remain uncertain.
- The company depends on TheraCour for licensed technology and development work. TheraCour is controlled by CEO and Chairman Anil Diwan. The COVID-19 license includes preferred-stock and cash milestones and a 15% royalty on defined net sales upon commercialization. The filing records a $935,088 stock-based license milestone expense during the nine months.
- The filing identifies a material weakness in internal control over financial reporting, related to period-end review and adequate personnel/resources. It remained unremediated at March 31, 2022; management described a remediation committee and related efforts.
- COVID-19 disruptions could hinder clinical-trial enrollment and access to financing. The company also disclosed dependence on external collaborators, limited drug-development experience, and uncertainty in development cost and timing estimates. It reported no pending or threatened legal proceedings to its knowledge and no off-balance-sheet arrangements.
- The filing contains a small net-loss discrepancy: the statements report third-quarter net loss of $1,792,664, while the MD&A states $1,792,644 in one passage. The financial statements’ figure is used above.
Important facts for investors to verify
- Confirm the correct reporting period: this is the quarter ended March 31, 2022, not 2021 Q3.
- Track whether an IND or equivalent submission is accepted and whether human trials actually begin, including timing, location, design, and funding.
- Assess cash runway against current and expected trial spending, and the company’s ability to raise additional capital without significant dilution.
- Review the evidence behind candidate safety and efficacy claims, distinguishing preclinical findings from clinical results.
- Examine related-party terms, outstanding TheraCour balances and advances, license milestones, royalties, and governance safeguards.
- Monitor remediation of the disclosed material weakness and the accuracy of subsequent financial reporting.